Skip to content

Ultrasound vs. Auscultation for Optimal Depth of the Cuffless RAE Tube

Ultrasound-guidance Versus Auscultation to Confirm Optimal Insertion Depth of the Cuffless Oral Ring-Adair-Elwyn (RAE) Endotracheal Tube in Pediatric Patients

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04246411
Enrollment
0
Registered
2020-01-29
Start date
2020-02-01
Completion date
2021-12-31
Last updated
2020-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Child, Intubation Complication, Ultrasonography

Brief summary

The aim of this study is to compare the ultrasound-guidance versus auscultation to confirm optimal insertion depth of the cuffless oral Ring-Adair-Elwyn (RAE) endotracheal tube in pediatric patients undergoing general anesthesia.

Interventions

BEHAVIORALUltrasound-guided determination of cuffless RAE tube depth

1. Measurement of Carina-T2 mid-vertebra length from preoperative Cheat PA 2. Ultrasound-guided detection of endobronchial intubation depth by loss of lung sliding sign in the left lung field. 3. Withdrawal of the cuffless RAE tube using the Carina-T2 mid-vertebra length for optimal positioning

BEHAVIORALAuscultation-guided determination of cuffless RAE tube depth

1. Measurement of Carina-T2 mid-vertebra length from preoperative Cheat PA 2. Auscultation-guided detection of endobronchial intubation depth by loss of breathing sound in the left lung field 3. Withdrawal of the cuffless RAE tube using the Carina-T2 mid-vertebra length for optimal positioning

Sponsors

Seoul National University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
No minimum to 7 Years
Healthy volunteers
Yes

Inclusion criteria

* Children age under 7 years * Undergoing general anesthesia * Endobronchial intubation with cuffless oral RAE tube

Exclusion criteria

* Pulmonary disease * Active upper respiratory tract infection * History of upper or lower respiratory tract infection within 2 weeks * Emergent operation * Unstable vital sign

Design outcomes

Primary

MeasureTime frameDescription
The proportion of optimal location of the cuffless Oral RAE tube (%)during operation (until endotracheal extubation) up to 18 hour after inductionThe distance between the tip of cuffless RAE tube and right pulmonary artery is within the -5mm \ +5mm value of the distance between the T2 mid-vertebra and carina (optimal depth)

Secondary

MeasureTime frameDescription
Distance between the optimal depth and the relocated depthduring operation up to 18 hour after inductionDistance between the optimal depth and the relocated depth
Subglottic diameter at the cricoid cartilage levelduring operationSubglottic diameter at the cricoid cartilage level using neck US
ID and OD of optimal cuffless oral RAE tubeduring operation up to 18 hour after inductionInternal and external diameter of optimal cuffless oral RAE tube
Time from intubation to confirming the tube depthduring operation up to 18 hour after inductionTime from intubation to confirming the tube depth (seconds)
M-distance (between the carina and the T2 mid-vertebra)during operation up to 18 hour after inductionThe distance between T2 mid-vertebra and the carina)
Airway leakage pressureduring operation up to 18 hour after inductionAirway leakage pressure measured by manual ventilation with APL(Adjustable pressure-limiting) valve
Incidence of the intraoperative airway-related eventsduring operation up to 18 hour after inductionaccidental extubation, endobronchial intubation, desaturation (SpO2 \< 95%), etc
Incidence of the airway-related symptoms after extubationup to 18 hour after inductionhoarseness, stridor, laryngospasm, chest retraction, etc
Distance between the optimal depth and the manufacturer's recommended depthduring operation up to 18 hour after inductionDistance between the optimal depth and the manufacturer's recommended depth

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026